KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Profit After Tax (2016 - 2025)

Jazz Pharmaceuticals has reported Profit After Tax over the past 16 years, most recently at $203.5 million for Q4 2025.

  • Quarterly results put Profit After Tax at $203.5 million for Q4 2025, up 6.45% from a year ago — trailing twelve months through Dec 2025 was -$356.1 million (down 163.58% YoY), and the annual figure for FY2025 was -$356.1 million, down 163.58%.
  • Profit After Tax for Q4 2025 was $203.5 million at Jazz Pharmaceuticals, down from $251.4 million in the prior quarter.
  • Over the last five years, Profit After Tax for JAZZ hit a ceiling of $251.4 million in Q3 2025 and a floor of -$718.5 million in Q2 2025.
  • Median Profit After Tax over the past 5 years was $52.0 million (2022), compared with a mean of $3.3 million.
  • Biggest five-year swings in Profit After Tax: plummeted 580.95% in 2022 and later skyrocketed 4114.94% in 2023.
  • Jazz Pharmaceuticals' Profit After Tax stood at -$35.4 million in 2021, then plummeted by 580.95% to -$240.7 million in 2022, then skyrocketed by 139.11% to $94.2 million in 2023, then skyrocketed by 102.98% to $191.1 million in 2024, then increased by 6.45% to $203.5 million in 2025.
  • The last three reported values for Profit After Tax were $203.5 million (Q4 2025), $251.4 million (Q3 2025), and -$718.5 million (Q2 2025) per Business Quant data.